1. In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
- Author
-
Rocha-Santos G, Cuba GT, Cayô R, Streling AP, Nodari CS, Gales AC, Pignatari ACC, Nicolau DP, and Kiffer CRV
- Subjects
- Aztreonam administration & dosage, Aztreonam pharmacology, Cephalosporins pharmacology, Clavulanic Acids administration & dosage, Clavulanic Acids pharmacology, Drug Synergism, Gene Expression Regulation, Bacterial drug effects, Gene Expression Regulation, Enzymologic drug effects, Microbial Sensitivity Tests, Tazobactam pharmacology, Ticarcillin administration & dosage, Ticarcillin pharmacology, beta-Lactamases genetics, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents pharmacology, Pseudomonas aeruginosa drug effects, beta-Lactamases metabolism
- Abstract
Minimal inhibitory concentrations (MICs) of ticarcillin/clavulanic acid (TLc), ceftolozane/tazobactam (C/T), and aztreonam (AT) were determined for 6 SPM-1-producing Pseudomonas aeruginosa (PSA) using Etest® strips and the synergistic effect of such antimicrobials against was evaluated by gradient diffusion strip crossing (GDSC) test. The fraction inhibitory concentration indexes (FICI) were calculated and showed a synergistic (n = 3) and additive (n = 2) effects of TLc + AT against SPM-1 producers, while TLc + C/T combination caused no effect. Average MIC reduction of TLc and AT by GDSC was 3-fold and 2-fold dilutions, respectively. Thus, TLc + AT might be a candidate as a combination therapy to treat SPM-1-producing PSA infections., Competing Interests: Declaration of Competing Interest G.T.C. has recently received research funding and/or consultation fees from MSD, Eurofarma, Pfizer and Sanofi. A.C.G. has recently received research funding and/or consultation fees from Bayer, Cristália, InfectoPharm, Eurofarma, Pfizer, MSD, and Zambon. D.P.N. consultant, speaker bureau member or have received research funding from Allergan, Bayer, Cepheid, Merck, Melinta, Pfizer, Wockhardt, Shionogi, and Tetraphase. C.R.V.K. consultant, speaker bureau member or have received research funding from Pfizer, Eurofarma, Johnson & Johnson, Biotest AG and New Objective outside the submitted work; Other authors have nothing to declare. This study was not financially supported by any Diagnostic/Pharmaceutical company. This work was partially presented as a poster (P2800) during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, 2019., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF